Ertugliflozin Lowers Uric Acid and Reduces Gout Risk in Type 2 Diabetes Patients with CVD, VERTIS CV Analysis Medha Baranwal24 Sept 2024 9:00 AM ISTCanada: Recent post hoc analyses from the VERTIS CV trial reveal promising results for ertugliflozin, a medication used to manage type 2 diabetes. The...
Dulaglutide Offers Dual Benefits for Elderly: Improved Blood Sugar Control and Knee OA Pain Relief, Study Finds Medha Baranwal24 Sept 2024 8:00 AM ISTIndia: A recent study has shed light on the dual benefits of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in managing both blood...
Bariatric surgery outperforms GLP-1 diabetes drugs for kidney protection suggests Cleveland Clinic study Dr. Kamal Kant Kohli24 Sept 2024 7:30 AM ISTA Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a...
Neuropathy Impact on Outcomes and Efficacy in HF Patients with Type 2 Diabetes: Insights from DAPA-HF and DELIVER Trials Dr.Niharika Harsha B23 Sept 2024 8:45 AM ISTNew research found that Dapagliflozin reduces the relative and absolute risk of death and heart failure-related hospitalization due to diabetic...
Metformin Associated with Lower Mortality Rates in Diabetes Patients With Heart Failure: Study Medha Baranwal21 Sept 2024 9:00 AM ISTChina: A recent meta-analysis has provided compelling evidence regarding the use of metformin in patients with type 2 diabetes mellitus (T2DM) who...
Widely used test for gestational diabetes misses 70% of cases, finds research Dr. Kamal Kant Kohli21 Sept 2024 7:30 AM ISTWhen screening pregnant women for gestational diabetes, casual blood glucose testing misses 70% of the cases. This Kobe University study should...
Real-World Analysis of Tirzepatide Reveals Comparable Safety Profile to GLP-1 Receptor Agonists Medha Baranwal20 Sept 2024 9:30 AM ISTItaly: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety profile of tirzepatide...
Weekly Insulin Efsitora Noninferior to Daily Insulin Degludec for Type 2 Diabetes Management: Phase 3 Trial Medha Baranwal19 Sept 2024 7:00 AM ISTUSA: A recent clinical trial (QWINT-2) has revealed that efsitora, a new once-weekly insulin, is as effective as the well-established once-daily...
Bariatric surgery may arrest worsening of Diabetic foot complications among patients with type 2 diabetes: Study Dr Riya Dave18 Sept 2024 8:30 AM ISTResearchers have documented that bariatric surgery is associated with a very significant risk reduction of diabetes-related foot complications (DFC)...
Replacing ultra-processed foods in diet reduces type 2 diabetes risk: Lancet Dr. Kamal Kant Kohli18 Sept 2024 6:45 AM ISTPeople who eat more ultra-processed foods (UPF) are at increased risk of developing type 2 diabetes, but this risk can be lowered by consuming less...
Once-Weekly Insulin Efsitora Noninferior to Daily Basal Insulin in T2D, reveal QWINT Trials Dr. Kamal Kant Kohli17 Sept 2024 8:30 AM ISTEli Lilly and Company today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once weekly insulin...
Medical Bulletin 16/ September/ 2024 Dr. Garima Soni16 Sept 2024 3:00 PM ISTHere are the top medical news for the day:Experimental mRNA Cancer Vaccine Shows Potential for Advanced Stage Cancer Patients in Phase 1 TrialInterim...
